8-K: Ivonescimab Shows Significant OS Benefit in NSCLC Trial

Summit Therapeutics' partner Akeso announced positive Phase III HARMONi-A trial results for ivonescimab, demonstrating a statistically significant overall survival benefit in EGFR-mutated NSCLC patients.

Summary

• Summit Therapeutics' partner, Akeso, Inc., published results from the Phase III HARMONi-A trial, conducted in China, evaluating ivonescimab combined with platinum-doublet chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who have progressed after treatment with an EGFR tyrosine kinase inhibitor.
• Ivonescimab plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) compared to chemotherapy alone, achieving a hazard ratio (HR) of 0.74 (95% CI: 0.58, 0.95, p=0.019).
• Median OS was 16.8 months (95% CI: 14.5, 20.0) in patients treated with ivonescimab plus chemotherapy compared to 14.1 months (95% CI: 12.8, 16.3) for those treated with chemotherapy alone.
• The data cut-off for this analysis was April 2025, with a median follow-up time of 32.5 months.
• This marks the first Phase III study conducted with ivonescimab to achieve a statistically significant overall survival benefit.
• Ivonescimab demonstrated an acceptable and manageable safety profile, consistent with previous Phase III studies, evidencing a favorable benefit-risk profile.
• 18 patients (11.2%) in the ivonescimab plus chemotherapy arm discontinued due to treatment-related adverse events (TRAEs), compared to 10 patients (6.2%) in the chemotherapy alone arm.
• One patient (0.6%) in each arm died as a result of TRAEs.
• The most frequent TRAEs for ivonescimab treatment in combination with chemotherapy included decreased white blood cell count, anemia, and other laboratory abnormalities.
• Ivonescimab was approved for marketing authorization in China in May 2024, based on the HARMONi-A study's primary endpoint of progression-free survival.
• Summit is sponsoring the global HARMONi study, which previously showed a statistically significant PFS benefit (HR 0.52, p<0.0001) and, in a subsequent analysis (September 2025), an improved nominal p-value for OS (HR 0.78; p=0.0332).

Sentiment

Score: 9

Explanation: The filing reports highly positive Phase III clinical trial results for ivonescimab, demonstrating a statistically significant overall survival benefit in a challenging patient population where other therapies have failed. This represents a significant clinical and commercial milestone for the drug and the company, indicating strong potential for future success and addressing a high unmet medical need.

Positives

• Statistically significant and clinically meaningful improvement in overall survival (OS) in the HARMONi-A trial, with a hazard ratio of 0.74 (p=0.019).
• Median OS of 16.8 months for ivonescimab plus chemotherapy, compared to 14.1 months for chemotherapy alone.
• This is the first Phase III study with ivonescimab to achieve a statistically significant OS benefit, differentiating it from other agents.
• Ivonescimab demonstrated an acceptable and manageable safety profile, consistent with previous studies, indicating a favorable benefit-risk profile.
• The study counters the notion that testing molecules with anti-VEGF components leads to worsening OS over time.
• Ivonescimab has produced four positive Phase III studies after four readouts, highlighting its consistent efficacy.
• Over 40,000 patients have been treated with ivonescimab in either a clinical or commercial setting in China.
• The global HARMONi study, sponsored by Summit, demonstrated a statistically significant progression-free survival (PFS) benefit (HR 0.52, p<0.0001) and an improved nominal p-value for OS (HR 0.78, p=0.0332) in a subsequent analysis.
• Ivonescimab was granted Fast Track designation by the US Food & Drug Administration (FDA) for the HARMONi clinical trial setting.
• Ivonescimab was initially approved for marketing authorization in China in May 2024.

Negatives

• A higher percentage of patients discontinued ivonescimab plus chemotherapy due to treatment-related adverse events (11.2%) compared to chemotherapy alone (6.2%).
• The primary overall survival analysis for the global HARMONi study was not statistically significant (p=0.057), although a subsequent analysis showed an improved nominal p-value.

Risks

• The Company's ability to sell shares of common stock under the At-The-Market (ATM) Program.
• Conditions affecting the capital markets, general economic, industry, or political conditions, including geopolitical developments, trade policies, and monetary policies.
• The results of the Company's evaluation of the underlying data in connection with the development and commercialization activities for ivonescimab.
• The outcome of discussions with regulatory authorities, including the Food and Drug Administration.
• Uncertainties inherent in the initiation of future clinical trials, availability and timing of data, and their success.
• Global public health crises that may affect the timing and status of clinical trials and operations.
• Whether preliminary results from a clinical trial will be predictive of the final results, or whether early clinical trials or preclinical studies will be indicative of later clinical trials.
• Whether business development opportunities to expand the Company's pipeline, including through potential acquisitions or collaborations, will occur.
• Expectations for regulatory approvals.
• Laws and regulations affecting government contracts and funding awards.
• Availability of funding sufficient for the Company's foreseeable and unforeseeable operating expenses and capital expenditure requirements.
• Any change to ongoing trials could cause delays, affect future expenses, and add uncertainty to commercialization efforts and the successful completion of clinical development of ivonescimab.

Future Outlook

Summit intends to open clinical trial sites in the United States for a Phase III study in colorectal cancer (CRC) by the end of 2025. Ivonescimab has the potential to make a significant difference in the lives of patients facing cancer diagnoses. The company is actively engaged in multiple Phase III clinical studies for ivonescimab in various cancer types, including biliary tract cancer, breast cancer, pancreatic cancer, small cell lung cancer, and head and neck cancer, in addition to ongoing NSCLC trials.

Management Comments

• Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit, noted: "The overall survival results of the HARMONi-A study evidence the ability of ivonescimab to demonstrate an overall survival benefit in patients facing high unmet medical needs. This study counters the notion that testing molecules with anti-VEGF components leads to worsening OS over time. The improvement in OS with longer follow-up time and the statistically significant benefit in the HARMONi-A study provides clear differentiation in the unique mechanism of action of ivonescimab as compared to other agents available for patients today. The specifically engineered design of ivonescimab has produced four positive Phase III studies after four Phase III readouts, leading to over 40,000 patients receiving ivonescimab when considering the commercial setting in China. Ivonescimab has the potential to make a significant difference in the lives of patients facing cancer diagnoses."
• Robert W. Duggan, Chairman and Co-Chief Executive Officer at Summit, stated: "Today's results highlight and support ivonescimab's differentiated efficacy and tolerability profile, and its ability to produce positive outcomes where PD-1 therapies have not shown a benefit in previous Phase III studies. Today, the current landscape includes limited options for patients after TKI therapy. The safety profile demonstrated by ivonescimab in combination with chemotherapy, both in HARMONi-A and across the four positive Phase III study readouts, is both manageable and provides compelling evidence as to the benefit-risk profile of ivonescimab for patients seeking effective therapy while minimizing quality of life-impacting adverse events. We congratulate our partners at Akeso for these outstanding results, as the first Phase III study conducted testing ivonescimab also represents the first study demonstrating a statistically significant OS benefit, highlighting the impact ivonescimab may bring to patients around the globe facing malignancies with limited treatment options today."

Industry Context

The announcement highlights ivonescimab's success in a challenging patient population (EGFR-mutated NSCLC who have progressed after EGFR TKI treatment) where PD-1 monoclonal antibodies have previously been unsuccessful in Phase III global clinical trials. This positions ivonescimab as a potential breakthrough in a therapeutic area with high unmet medical needs and limited existing options. The bispecific antibody design, combining PD-1 blockade with anti-angiogenesis (VEGF blocking), is presented as a key differentiator, potentially offering a superior efficacy and tolerability profile compared to single-target therapies and countering previous notions about anti-VEGF components worsening overall survival.

Comparison to Industry Standards

• Ivonescimab demonstrated a statistically significant overall survival (OS) benefit (HR 0.74, p=0.019) in EGFR-mutated NSCLC patients who progressed after EGFR TKI treatment. This is a significant differentiation, as PD-1 monoclonal antibodies have previously failed to show such a benefit in Phase III global clinical trials for this specific patient population.
• The study results counter the notion that molecules with anti-VEGF components lead to worsening OS over time, suggesting an improved profile compared to some historical anti-VEGF agents.
• The safety profile of ivonescimab in combination with chemotherapy is described as manageable and consistent across four positive Phase III studies, providing a favorable benefit-risk profile compared to the limited options currently available for patients after TKI therapy.

Stakeholder Impact

• Shareholders: Highly positive impact due to successful clinical trial results, which de-risk the asset and enhance the company's valuation and future revenue potential.
• Patients: Significant positive impact by offering a new, effective treatment option with improved overall survival for EGFR-mutated, locally advanced or metastatic non-squamous NSCLC patients who have progressed after EGFR TKI treatment, addressing a high unmet medical need.
• Healthcare Providers: Provides a differentiated and effective new therapy for a challenging patient population, expanding treatment armamentarium.

Next Steps

• Summit intends to open clinical trial sites in the United States for a Phase III study in colorectal cancer (CRC) by the end of 2025.
• Akeso is actively conducting multiple Phase III clinical studies for ivonescimab in settings outside of NSCLC, including biliary tract cancer, breast cancer, pancreatic cancer, small cell lung cancer, and head and neck cancer.

Key Dates

Recommendation

The statistically significant overall survival benefit demonstrated by ivonescimab in the HARMONi-A trial, particularly in a patient population where PD-1 therapies have previously failed, represents a major de-risking event and a significant competitive advantage. This positive data, combined with the drug's Fast Track designation by the US FDA and existing marketing approval in China, strongly positions Summit Therapeutics for future regulatory approvals and commercial success in key markets. The potential to address a high unmet medical need with a differentiated mechanism of action makes this a compelling investment opportunity for seasoned investors.

Keywords

Ivonescimab, NSCLC, Non-Small Cell Lung Cancer, EGFR-mutated, Overall Survival, Phase III, HARMONi-A, Summit Therapeutics, Akeso, Oncology, Biopharmaceutical, Bispecific Antibody, PD-1, VEGF, Clinical Trial, Cancer Treatment, FDA Fast Track